Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
976 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (402)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03153982 | Ruxolitinib in Operable Head and Neck Cancer | terminated | Phase 2 | 16 | University of California, San FranciscoOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer(PDL1x41BB) | terminated | Phase 1 | 160 | Inhibrx Biosciences, IncINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT03452137 | A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck(IMvoke010) | terminated | Phase 3 | 406 | Hoffmann-La RocheINDUSTRY | 23 | Oct 9, 2024 | clinicaltrials |
| NCT04685798 | Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT | terminated | N/A | 8 | Washington University School of MedicineOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03370861 | How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes(MINING) | terminated | — | 54 | Washington University School of MedicineOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT03387111 | QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed | terminated | Phase 1 / Phase 2 | 4 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 5, 2024 | clinicaltrials |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 37 | PfizerINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT03601507 | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer | terminated | Phase 2 | 9 | University of ArizonaOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04659369 | Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC | terminated | Phase 1 | 21 | Taizhou Mabtech Pharmaceutical Co.,LtdINDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT05121948 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | terminated | Phase 1 | 35 | HiberCell, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04410874 | Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer(MUSIC-01) | terminated | Phase 1 / Phase 2 | 1 | Ivan LitvinovOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | terminated | Phase 1 / Phase 2 | 11 | NKGen Biotech, Inc.INDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT04624113 | Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | terminated | Phase 1 | 13 | Washington University School of MedicineOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04634825 | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer | terminated | Phase 2 | 62 | MacroGenicsINDUSTRY | 7 | Dec 20, 2023 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | terminated | Phase 1 | 14 | IpsenINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT02285543 | A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients | terminated | Phase 2 | 10 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03618134 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | terminated | Phase 1 / Phase 2 | 19 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02831933 | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma(ENSIGN) | terminated | Phase 2 | 11 | Eric Bernicker, MDOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | terminated | — | 20 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04193293 | A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 2 | SecuraBioINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01755650 | Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies | terminated | Early Phase 1 | 6 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT03912818 | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer | terminated | Phase 2 | 7 | Stanford UniversityOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT02524275 | Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 2 | 14 | University of NebraskaOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT00707655 | Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy | terminated | Phase 1 / Phase 2 | 8 | GenmabINDUSTRY | 3 | Aug 3, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT04688749 | Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage(DermaSense) | terminated | — | 50 | Aristotle University Of ThessalonikiOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT03740100 | Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations(HNSCC) | terminated | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT01824823 | Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence | terminated | Phase 2 | 3 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT02488629 | Study of SCB01A in Patient With Head and Neck Cancer | terminated | Phase 2 | 5 | SynCore Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 27, 2023 | clinicaltrials |
| NCT01992861 | MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer | terminated | — | 51 | University of WashingtonOTHER | 3 | Jun 26, 2023 | clinicaltrials |
| NCT03522584 | Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 6 | University of WashingtonOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT03827850 | FGFR Inhibitor in FGFR Dysregulated Cancer(FIND) | terminated | Phase 2 | 22 | Lung Cancer Group CologneOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | 1,333 | SWOG Cancer Research NetworkNETWORK | 2 | May 23, 2023 | clinicaltrials |
| NCT02345330 | Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC) | terminated | Phase 2 | 4 | OncoSec Medical IncorporatedINDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT03823131 | Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat | terminated | Phase 2 | 14 | Chase Heaton, MDOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT03802058 | Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer | terminated | Phase 2 | 24 | Wuhan UniversityOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT04110249 | Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer | terminated | N/A | 14 | Roswell Park Cancer InstituteOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides | terminated | Phase 1 | 56 | PfizerINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT03254927 | A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma | terminated | Phase 2 | 30 | Celldex TherapeuticsINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT04611321 | Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 15 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT04034225 | Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN | terminated | Phase 1 / Phase 2 | 25 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02582008 | Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy | terminated | Early Phase 1 | 9 | Wake Forest University Health SciencesOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT02917629 | ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03906526 | A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer | terminated | Phase 1 | 15 | CelgeneINDUSTRY | 1 | Feb 24, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 30, 2024source: clinicaltrials